KOREA WHO
-
-
CEO of GC Genome
Ki Chang-seok
Samsung-Trained Physician Leads GC Genome’s Global Push
-
Last Updated on Nov 14, 2025
-
CEO of GC Genome
Copy Url : https://www.koreawho.com/profile/KiChangseok- Life Summary
Ki Chang-seok is the CEO of GC Genome.
He aims to expand the company’s presence in the Middle East, Japan, the United States, and other regions to reshape the paradigm of the global early-diagnosis market.
He was born on November 7, 1969.
He graduated from Seoul National University College of Medicine. He earned a master’s degree in medicine from Korea University Graduate School and a doctorate in medicine from Sungkyunkwan University Graduate School.
He worked as an intern (training physician) at Seoul National University Hospital and as a resident (clinical trainee) in the Department of Laboratory Medicine at Samsung Medical Center.
He served as the chief of pathology at the Armed Forces Daejeon Hospital before being appointed a professor in the Department of Laboratory Medicine at Sungkyunkwan University School of Medicine.
In 2018, he was recruited as CEO of GC Genome (then called GC Green Cross Genome), a company specializing in genomic analysis.
He is a CEO with a background as a specialist in laboratory medicine.
He places strong emphasis on technological innovation and research and development.
#GCGenome #KiChangseok #earlydiagnosis #genomics #healthcare #laboratorymedicine #globalexpansion #medicaltechnology #innovation #biotech
He aims to expand the company’s presence in the Middle East, Japan, the United States, and other regions to reshape the paradigm of the global early-diagnosis market.
He was born on November 7, 1969.
He graduated from Seoul National University College of Medicine. He earned a master’s degree in medicine from Korea University Graduate School and a doctorate in medicine from Sungkyunkwan University Graduate School.
He worked as an intern (training physician) at Seoul National University Hospital and as a resident (clinical trainee) in the Department of Laboratory Medicine at Samsung Medical Center.
He served as the chief of pathology at the Armed Forces Daejeon Hospital before being appointed a professor in the Department of Laboratory Medicine at Sungkyunkwan University School of Medicine.
In 2018, he was recruited as CEO of GC Genome (then called GC Green Cross Genome), a company specializing in genomic analysis.
He is a CEO with a background as a specialist in laboratory medicine.
He places strong emphasis on technological innovation and research and development.
#GCGenome #KiChangseok #earlydiagnosis #genomics #healthcare #laboratorymedicine #globalexpansion #medicaltechnology #innovation #biotech
- Life Summary
- Career Highlights & Challenges
- · GC Genome’s BusinessGC Genome is an affiliate of the GC Green Cross Group and a company specializing in clinical genome analysis. Based on clinical data and genome analysis capabilities, it provides genome-based healthcare services across the entire life cycle, including pre- and post-natal genetic testing, disease-prediction diagnostics, rare-disease genome interpretation, and cancer precision diagnostics.
- · GC Genome’s GovernanceGC Genome operates as a single business entity with no consolidated subsidiaries as of June 30, 2025.
- · 2025 ai-CANCERCH Vision SymposiumGC Genome held the “2025 ai-CANCERCH Vision Symposium” for medical professionals on October 22, 2025, at EL Tower near Yangjae Station in Seoul.
- · ai-CANCERCH Targets Middle East MarketGC Genome held offline seminars on the multi-cancer early detection service “ai-CANCERCH” in Bahrain and Saudi Arabia from September 15 to 18, 2025, and signed strategic partnerships with major local institutions.
- · Medical Normalization Boosts Demand for Diagnostic TestingGC Genome recorded revenue of KRW 14.6 billion (US$ 10.5 million), operating profit of KRW 200 million (US$ 0.1 million), and net profit of KRW 200 million (US$ 0.1 million) in the first half of 2025. Compared to the same period a year earlier, revenue increased 23.8 percent, and both operating and net results returned to the black.
- · Japanese Patent Granted for Multi-Cancer Early Detection TechnologyKi Chang-seok is focusing on securing patents to support global market expansion.
- · KOSDAQ ListingGC Genome was listed on the KOSDAQ market on June 11, 2025.
- · UAE Supply Deal for Prenatal Test G-NIPTGC Genome signed a supply agreement in May 2025 with Bollwort Medical, a medical device distributor in the United Arab Emirates, for the noninvasive prenatal test “G-NIPT.”
- · Appointment as CEO of GC GenomeGC Genome (then GC Green Cross Genome) held an extraordinary shareholders’ meeting and board meeting on June 8, 2018, and appointed Ki Chang-seok as CEO.
- · GC Genome’s JourneyFounded in 2013 under the name “GC Green Cross Genome.” It established its corporate research institute.
- Vision and Goals
- Market and Social Evaluation
- Notable Incidents & Legal Affairs
- Professional Timeline
- Educational Background
- Awards & Recognitions
- Additional Information
- Notable Quotations
- Infographic & Photos